Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton F Stewart

Showing results (121-130 of 220) with videos related to

Pageof 22
Sort By:
Cancer Chemotherapy and Pharmacology|July 8, 2005
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumorsCarlos Rodriguez-Galindo, Kristine R Crews, Clinton F Stewart, et al.
Neuro-Oncology|February 5, 2011
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor ConsortiumIan F Pollack, Clinton F Stewart, Mehmet Kocak, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumorsNajat C Daw, Victor M Santana, Lisa C Iacono, et al.
Cancer|January 2, 2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumorsLisa M McGregor, Sheri L Spunt, Victor M Santana, et al.
Blood|September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaEric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapyKristine R Crews, Clinton F Stewart, Dana Jones-Wallace, et al.
Cancer Investigation|October 6, 2005
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancerHeidi H Gillenwater, Jeannine S McCune, Celeste Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade gliomaAlberto Broniscer, Suzanne J Baker, Clinton F Stewart, et al.
Neuro-Oncology|October 21, 2003
Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237ZoAnn E Dreyer, Richard P Kadota, Clinton F Stewart, et al.
Pageof 22

Showing results (121-130 of 220) with videos related to

Sort By:
Pageof 22
Cancer Chemotherapy and Pharmacology|July 8, 2005
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumorsCarlos Rodriguez-Galindo, Kristine R Crews, Clinton F Stewart, et al.
Neuro-Oncology|February 5, 2011
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor ConsortiumIan F Pollack, Clinton F Stewart, Mehmet Kocak, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumorsNajat C Daw, Victor M Santana, Lisa C Iacono, et al.
Cancer|January 2, 2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumorsLisa M McGregor, Sheri L Spunt, Victor M Santana, et al.
Blood|September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaEric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapyKristine R Crews, Clinton F Stewart, Dana Jones-Wallace, et al.
Cancer Investigation|October 6, 2005
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancerHeidi H Gillenwater, Jeannine S McCune, Celeste Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade gliomaAlberto Broniscer, Suzanne J Baker, Clinton F Stewart, et al.
Neuro-Oncology|October 21, 2003
Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237ZoAnn E Dreyer, Richard P Kadota, Clinton F Stewart, et al.
Pageof 22